Published: 05 December 2023
The Institute of Infection and Immunity hosted its annual International Consortium for Trials of Chemotherapeutic Agents in Tuberculosis (INTERTB) symposium on Monday 13th November.
The meeting was organised by Professor Amina Jindani, who has dedicated her career to tuberculosis research, and was attended by over 120 of the world's leading experts in TB treatment.
Colleagues from the UK, USA and Europe came together to share new scientific findings and advancements in TB research. The symposium was opened by St George’s Deputy Vice-Chancellor for Research and Enterprise, Professor Jon Friedland, with sessions chaired by Professor Julian Ma, Director of St George’s Institute for Infection and Immunity, and Dr Patrick Phillips from the University of California.
Highlights of the symposium were hearing about the results of key trials including the RIFASHORT, RIFASHORT Persister, TRUNCATE-TB, Assessing Pretomanid for Tuberculosis (APT) and PanACEA STEP2C, which all aim to identify shorter and more effective treatment regimes for the disease.
Group discussions focused on the challenges of developing new drugs and vaccines for TB, and the future of TB research.
“The INTERTB Symposium was a huge success. There were open, lively, and informative discussions about the great leaps forward in TB research from our scientific community, and the best ways forward for future trials.”
- Amina Jindani, Professor of Tuberculosis Therapeutics who orchestrated the INTERTB Symposium -
“St George’s is home to world-class tuberculosis research and every year we’re proud to host this major international conference. I look forward to convening with our colleagues again next year as we continue to celebrate and focus our combined efforts on eradicating TB.”
- Professor Jon Friedland, Deputy Vice-Chancellor for Research and Enterprise -
Research at St George’s Institute for Infection and Immunity